Want to see DE:DMP full AI Analyst Report?
DMP Stock Chart & Stats
€46.20
€0.00(0.00%)
At close: 4:00 PM EST
€46.20
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€31.70 - €51.90
Previous CloseN/A
Volume747.00
Average Volume (3M)18.50K
Market Cap
€2.25B
Enterprise Value€3.19B
Total Cash (Recent Filing)€254.00M
Total Debt (Recent Filing)€1.04B
Price to Earnings (P/E)16.6
Beta0.45
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.34%
Share Statistics
EPS (TTM)2.69
Shares Outstanding49,540,810
10 Day Avg. Volume17,993
30 Day Avg. Volume18,498
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.05
Price to Sales (P/S)1.82
P/FCF Ratio15.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.00Price Target Upside12.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.67
Revenue Forecast (FY)€1.20B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained FCF near €198m with year-over-year growth and conversion (~82% of net income) indicates durable internal funding for capex, product launches, and debt reduction. Reliable cash conversion supports strategic options and reduces dependence on external financing over months.
Re-accelerating Revenue And Solid MarginsA strong revenue rebound coupled with healthy EBIT and net margins signals resilient demand and operating leverage in the core pharmaceutical portfolio. This profile supports sustainable profitability and reinvestment capacity if management preserves product mix and cost discipline.
Diversified Pharma And Manufacturing Business ModelMultiple revenue streams — branded generics, OTC consumer health and contract manufacturing — reduce single-market exposure. Vertical manufacturing capability improves margin control and utilization, giving structural resilience and recurring third‑party revenue over the medium term.
Bears Say
Elevated Leverage RemainsWhile improved from prior levels, a debt-to-equity near 1.4 still implies meaningful leverage that raises refinancing and interest-rate sensitivity. Elevated debt constrains strategic flexibility, increases fixed costs, and heightens downside risk if cash generation weakens.
Historical Margin VolatilityPast swings in margins suggest earnings depend on product mix, pricing/reimbursement and cost timing. This reduces predictability of operating profits and complicates budgeting and capital allocation, making medium-term earnings durability less certain.
OCF Lags Net Income; Working-capital VariabilityOCF around 0.62x of net income points to working-capital or timing pressures that can create cash volatility. Even with strong FCF, weaker OCF conversion raises short-term liquidity and operational risk if receivables or inventory trends worsen.
DMP FAQ
What was Dermapharm Holding SE’s price range in the past 12 months?
Dermapharm Holding SE lowest stock price was €31.70 and its highest was €51.90 in the past 12 months.
What is Dermapharm Holding SE’s market cap?
Dermapharm Holding SE’s market cap is €2.25B.
When is Dermapharm Holding SE’s upcoming earnings report date?
Dermapharm Holding SE’s upcoming earnings report date is Aug 25, 2026 which is in 42 days.
How were Dermapharm Holding SE’s earnings last quarter?
Dermapharm Holding SE released its earnings results on May 13, 2026. The company reported €0.84 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Dermapharm Holding SE overvalued?
According to Wall Street analysts Dermapharm Holding SE’s price is currently Undervalued.
Does Dermapharm Holding SE pay dividends?
Dermapharm Holding SE pays a Annually dividend of €0.88 which represents an annual dividend yield of 2.34%. See more information on Dermapharm Holding SE dividends here
What is Dermapharm Holding SE’s EPS estimate?
Dermapharm Holding SE’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dermapharm Holding SE have?
Dermapharm Holding SE has 49,540,810 shares outstanding.
What happened to Dermapharm Holding SE’s price movement after its last earnings report?
Dermapharm Holding SE reported an EPS of €0.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.294%.
Which hedge fund is a major shareholder of Dermapharm Holding SE?
Currently, no hedge funds are holding shares in DE:DMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dermapharm Holding SE Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€52.00 (12.55% Upside)
€52.00 (12.55% Upside)
Insider Transactions
Bought Shares
Worth €17.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.13%
12-Months-Change
Fundamentals
Return on Equity
21.44%
Trailing 12-Months
Asset Growth
7.62%
Trailing 12-Months
Company Description
Dermapharm Holding SE
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It undertakes the development, manufacturing, licensing, marketing, and sale of branded generic medicines, over-the-counter remedies, non-prescription natural health solutions, and various other healthcare items. Dermapharm's product range covers areas such as vitamins, minerals, nutritional supplements, dermatology, allergology, pain and inflammation management, cardiovascular support, gynecology, and urology, prominently featuring brands like Dekristol, Dekristolvit, Allergovit, and Tromcardin. Additionally, the company provides medical devices including bite away and Herpotherm, as well as specific pharmaceutical preparations like Momekort, a nasal spray for allergy symptoms, and Azedil, which functions as a nasal spray or eye drop. It also manages the importation of originator pharmaceuticals under the axicorp brand. Furthermore, Dermapharm supplies herbal extracts and natural active ingredients for application in phytopharmaceuticals, nutraceuticals, and cosmetics. Its clientele encompasses pharmaceutical wholesalers, retail pharmacies, hospitals, and health food stores. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
DMP Stock 12 Month Forecast
Average Price Target
€52.00
▲(12.55% Upside)
Technical Analysis
Options Prices
Currently, No data available
---








